Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Lulizumab Pegol · BMS-931699

Monoclonal antibody · developed by BRISTOL MYERS SQUIBB

Phase 1/2 Most advanced trial (none active)
BMY Developer
1 Registered trials

What is Lulizumab Pegol?

Lulizumab Pegol is an investigational antibody studied in Living-Donor Kidney Transplant, Kidney Transplant Recipients.

At a glance

Also known as
BMS-931699
Drug type
Monoclonal antibody
Therapy area
Renal & urology
Developer
BRISTOL MYERS SQUIBB (BMY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
LCT264LTYE

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04066114 Phase 1/2 Living-Donor Kidney Transplant Completed BMY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Kidney Transplant RecipientsLiving-Donor Kidney Transplant

More from BRISTOL MYERS SQUIBB

Apixaban FDA approved Belatacept FDA approved Deucravacitinib FDA approved Ipilimumab FDA approved Lisocabtagene Maraleucel FDA approved Luspatercept FDA approved Mavacamten FDA approved Nab-paclitaxel FDA approved Nivolumab FDA approved Ozanimod FDA approved Relatlimab FDA approved Repotrectinib FDA approved

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BMY page.

Follow BMY, the company behind Lulizumab Pegol

See BMY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BMY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.